PLACEBO TO MATCH STERILE DP SOLUTIONS – PERSPECTIVES PART 1

Myrna Monck: BPFx Solutions LLC affiliated with SCxCMC Solutions

Table of Contents

Introduction

In randomized clinical trials in which one or more of statisticians, investigators, nurses and patient groups involved in the trial are blinded to the treatment, it is essential to maintain the integrity of the blind. The characteristics of the placebo dosage form that is designed to maintain the blind are essential. This is particularly true for parenteral dosage forms, where even subtle differences in appearance, viscosity, or injection experience can compromise the validity of study results. A matching placebo for injectables must replicate the active product's perceived physical and sensory characteristics in the absence of the active pharmaceutical ingredient (API). This includes matching color, clarity, osmolality, pH; and viscosity and injection feel (for syringe administration), all while maintaining sterility and stability under the conditions of the administration setting.

Manufacturing such placebos presents unique challenges:

- **Sterile processing** and **aseptic filling** must meet stringent GMP standards.
- **Excipient selection** must ensure inertness (relative to active ingredient) while mimicking the active formulation.
- **Color matching or masking and viscosity matching approaches** are often required for biologics and complex injectables.
- **Syringe product matching** must include primary container and closure components and obviate visual cues that can distinguish a placebo from an active dosage form.

This is the first part of a two-part series. Part 1 focuses on placebo design, dosage form considerations related to routes of administration and formulation.

Context and strategic rationale

Background context - Placebo Control

The International Conference on Harmonization ICH E10 guidance (1) sets expectations for the choice of control groups in clinical trials. The guidance states that the major purpose of the control group is "to allow discrimination of patient outcomes…caused by test treatment, from outcomes caused by other factors…". A placebo controlled clinical trial is a blinded randomized trial design where one or more groups are blinded to maintain the integrity of trial results. Clinical trials may incorporate the use of placebos for various purposes. For example, the design may include substitution of placebo with the test drug at a fixed point in the trial. The replacement of placebo with drug, in this case, is to confirm that clinical results can be attributed to the drug of interest. In other clinical trials, such as a double-blind double dummy trial, one or more placebo products are administered to both patient groups particularly where multiple dosage forms are used.

A clinical study, in which the effectiveness of a drug is tested against a placebo control, generally requires initiation and maintenance of the blind initially and throughout the trial until the data are processed and results are assessed to determine if the study endpoints have been met.

For any of these formats, it is essential to integrate the clinical trial design, the route of administration, the person administering each placebo or active investigative product (e.g. by a nurse, caregiver or self-administered) and physical location (e.g. clinic or home administration) when considering placebo to match options and design.

Decision – When to Manufacture a Placebo to Match

The cost and time associated with designing, planning, scheduling and budgeting for a placebo-controlled study is substantially similar to that of a drug product. Therefore, careful consideration of placebo characteristics that would meet the definition of a control should follow a systematic approach and result in a target placebo profile. The resulting placebo should be fit for purpose for the clinical trial and may or may not require the design and manufacture of a custom placebo.

Discrimination Testing

Application of a sensory discrimination study can aide in placebo target decisions. These are statistical studies that can be designed to assess whether perceptible differences exist between the investigational medicinal product and potential placebo options.

Should the statistical evaluation conclude that a matching placebo is necessary, the findings provide a robust foundation for proceeding with the appropriate placebo product.

Dosage form and Route of Administration considerations

The target attributes of a placebo to match injectable drug product largely depends on the drug product image and general physical properties of the dosing solution.

Intravenous Administration – Placebo in Vial

Sterile drug product vials are available in various formats, such as lyophilized powders for reconstitution, and solutions or concentrates intended for dilution. For an intravenous (IV) route of administration, a concentrate will undergo a preparation step in which the drug product is diluted with sterile saline or dextrose solutions before administration. The appropriate placebo to select in these cases depends on the users' ability to distinguish between the placebo and active drug solutions

Subtle visual differences between active and placebo investigational products can often be mitigated using various approaches, physical or operational, to help maintain the blind when the appearance of the placebo and active cannot be matched directly. A custom matching placebo should be considered if the target placebo attributes cannot be met by other means.

Subcutaneous Administration – Placebo in Vial, Syringe Administration

A single drug product vial presentation can be designed for multiple doses providing clinical study flexibility. If the route of administration is subcutaneous injection, dosing is commonly performed using syringes where the dosing solution is withdrawn into a syringe. Similar decision frameworks to those used for intravenous (IV) placebo matching can be applied to these

scenarios to determine appropriate placebo options. Syringe attributes should be considered when evaluating sensory cues.

Pre-Filled Syringe Combination Products

When pre-filled syringes (PFS), with or without integrated delivery devices such as safety syringes/features or autoinjectors, are required for a clinical trial—and the combination product is used "as is" without modification—a matching placebo may be the preferred placebo option. This choice arises primarily, but not exclusively, because of the complexity of the dosage form.

General considerations – Vials, Syringes, Combination Products

Temporal factors should be included in the placebo strategy for all dosage forms. Whilst a chosen placebo may match the drug product characteristics at the time of testing, these results may depend on the age of specific placebo, drug product or combination product. Consideration should be given to temporal changes that may occur in one or more sensory characteristics of the dosage form. Furthermore, attributes of new versus aged devices assembled with pre-filled syringes may change over the life of the product. Overall, the drug product expert must include temporal changes in assessment of the placebo vs active since they may affect the suitability of the placebo as a control for the active dosage form.

Formulation Strategy for Sterile Injectable Placebos

The quantitative composition of a matching placebo should closely reflect that of the investigational drug product solution to ensure the placebo is fit for purpose [2]. As placebos are commonly used as control agents in clinical studies [1], they must replicate the sensory characteristics of the investigational medicine—such as appearance, viscosity, and injection experience—while excluding the active pharmaceutical ingredient.

Impact of Formulation on Blinding and Patient Experience

The patient experience with a placebo medication is significantly influenced by its formulation, the choice and concentration of excipients. A straightforward strategy for developing a matching placebo control is to include all excipients present in the investigational drug product, using target quantitative compositions that closely mirror the original formulation. Whether using the drug product formulation constituents or designing a unique formulation with excipients that match all sensory aspects of the drug product formulation, a target placebo profile should be set to ensure the placebo meets the requirements of the clinical study design.

As a first intent, multicompendial, high-purity, parenteral-grade excipients should be selected to ensure safety, consistency, and regulatory compliance in placebo formulation [3].

Finally, special attention should be paid to patient-reported experiences and adverse-event signals, such as injection site reactions (e.g., redness, swelling) or pain upon injection, as these may differ between placebo and active treatment leading to unintentional unblinding. Therefore,

data from all clinical trials—including adverse event reports—should be carefully reviewed when selecting a matching placebo formulation with non-active excipients, to ensure that all relevant patient tolerability factors are considered.

Conclusions

The decision to develop a matching parenteral placebo is a strategic component of the clinical development process and should be initiated early in the program. One critical consideration is the sensory characteristics of the investigational drug product and whether one of many placebo options is suitable to act as a control for the active drug product. This requires a formal evaluation of alternatives using appropriately designed statistical tests. The approach can streamline development timelines and reduce costs across both clinical and product development plans.

References

1) International Council for Harmonisation (ICH). (2018). ICH Harmonised Guideline: Choice of Control Group and Related Issues in Clinical Trials E10. https://database.ich.org/sites/default/files/E10_Guideline.pdf Accessed on 24 Aug 2025.
2) https://singota.com/wp-content/uploads/2024/01/Factors-in-Developing-Injectable-Drug-Placebo-Formulations-for-Pharmaceutical-Clinical-Trials.pdf Accessed 24 August 2025
3) https://www.pharmaexcipients.com/excipients-for-parenterals/#:~:text=Purity:%20Parenteral%20excipients%20must%20be,European%20Medicines%20Agency%20(EMA). Accessed 21 August 2025